Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·

Lack of effect of doxycycline on disease activity and joint damage in patients with rheumatoid arthritis. A double blind, placebo controlled trial

Publication files not online:

Author: Laan, W. van der · Molenaar, E. · Ronday, K. · Verheijen, J. · Breedveld, F. · Greenwald, R. · Dijkmans, B. · Tekoppele, J.
Institution: Gaubius instituut TNO
Source:Journal of Rheumatology, 9, 28, 1967-1974
Identifier: 236218
Keywords: Health · Biomedical Research · Doxycycline · Pyridinolines · Rheumatoid arthritis · deoxypyridinoline · doxycycline · placebo · pyridinoline · clinical examination · clinical trial · controlled clinical trial · controlled study · crossover procedure · disease activity · double blind procedure · erythrocyte sedimentation rate · foot radiography · hand radiography · joint destruction · joint stiffness · laboratory test · major clinical study · randomized controlled trial · scoring system · Adolescent · Adult · Aged · Aged, 80 and over · Analysis of Variance · Arthritis, Rheumatoid · Chi-Square Distribution · Cross-Over Studies · Dose-Response Relationship, Drug · Double-Blind Method · Doxycycline · Drug Administration Schedule · Female · Follow-Up Studies · Humans · Male · Middle Aged · Pain Measurement · Reference Values · Severity of Illness Index · Treatment Failure · Treatment Outcome


Objective. To investigate the effects of doxycycline on disease activity and joint destruction in patients with rheumatoid arthritis (RA). Methods. A 36 week double blind, placebo controlled crossover trial was conducted. Patients (n = 66) received 50 mg doxycycline or placebo twice a day during 12, 24, or 36 weeks. Patient assessments were performed before the treatment was administered, at 6, 12, 24 and 36 weeks of treatment, and finally at 4 weeks after cessation of treatment. Patient assessments, swollen and tender joint counts, duration of morning stiffness, erythrocyte sedimentation rate, and Modified Disease Activity Score were used as measures of disease activity. Effects on joint destruction were assessed by urinary excretion of the pyridinolines hydroxylysylpyridinoline and lysylpyridinoline and by scoring radiographic damage of hands and feet before and after treatment. Results. The changes of clinical or laboratory disease activity measures, pyridinoline excretion, or progression of radiographic joint damage during doxycycline or placebo treatment did not differ significantly. Conclusion. The results indicate that 50 mg doxycycline twice a day provided no therapeutic benefit for patients with RA.